AUXILIUM ANNOUNCES TOP-LINE RESULTS FROM AA4500 STUDY

A A

Auxilium Pharmaceuticals has reported top-line results from a pivotal efficacy study of AA4500, its injectable enzyme product, in patients with Dupuytren's disease.

The randomized, double-blind, placebo-controlled pivotal efficacy study showed that a local injection of AA4500 was highly effective in the treatment of Dupuytren's contracture. In this trial involving a total of 35 patients, 23 patients were randomized to receive AA4500 (up to three injections) and 12 patients were randomized to patients were randomized to receive placebo, with the goal of reaching therapeutic success.